ABL is a global leader in immunomonitoring, offering expert biomarker testing services to advance therapies from discovery to clinical stages.

Our latest tweets

What do all therapies under development have in common?
Whether in preclinical or clinical stage, they all need robust and reliable biomarker monitoring tools to track and characterize their biological effect.
ABL services address most critical requirements:

Study design

Sampling plans and logistics

Assay development and validation

Integrated approach to utilizing multiple instrument platforms

Efficient study execution and data analysis

Flexible options for alternative study approaches

PBMC Network

Measuring the impact of a drug on the functionality of immune cells generally relies on peripheral blood mononuclear cells (PBMC). Preserving their viability and, most importantly, their functional integrity is critical for generating reliable, unbiased data. In order to ensure sample preservation, ABL has developed a network of international laboratories for timely (<8H) and high quality PBMC processing & storage using harmonized SOPs. This network is supporting several multi-site clinical trials in Europe and North America.

Cell viability at lab site >90%
Cell viability after thawing >80%
Preserved function

We support dozens of preclinical and clinical studies evaluating the safety and efficacy of several immunotherapies, including monoclonal antibodies (MAbs), Antibody Drug conjugates (ADCs), therapeutic vaccines, Chimeric Antigen Receptor T cells (CAR-T cells), oncolytic virotherapies, etc.

Anti-PD1, Anti-CTLA4, CAR T cells, Neoantigens


Infectious diseases
Therapeutic vaccines, oncogenic viruses (HPV, HCV, HBV), HIV

Infectious diseases

Autoimmune conditions
Crohn’s Disease, Multiple Sclerosis, Rheumatoid Arthritis, Biological Response Modifiers

Autoimmunity / Inflammation

Neurodegenerative diseases
Alzheimer’s, Parkinson’s, Diabetes, NASH

Other diseases

ABL Lyon is certified according to ISO 9001:2008 standards since October 2011.
In addition to the ISO standards, our QMS is based on Good Laboratory Practices (as revised in 1997 issued by the OCDE), and uses the following referential as guidance:

GCP: Good Clinical practices (CPMP/ICH/135/95).
GCLP: Good Clinical Laboratory Practices (EMA/INS/GCP/532137/2010)
GCLP: Good Clinical Laboratory Practices (WHO)
GCLP: Good Clinical Laboratory Practices (published by Research Quality Association (RAQ – December 2012)
Communication plan
  • Meetings
  • SecureRaw data availability
  • Total confidentiality
  • Timely troubleshooting report
  • Questioning unexpected results
Technical Protocol
  • Scientific expertise
  • Understand and Qualify the need
  • Offier the most relevant methods
    • Optimize, validate methods
    • Explore new Approaches
  • Full study report
  • Critical analysis of generated data
  • Secured archiving of study results
Quality plan
  • GCLP / ISO 9001:2008/2015
  • Secure system
  • Sample management
  • Stringent QCs criteria
  • Equipment maintenance
  • Full traceability
International footprint

Wherever you are in your product development pipeline, ABL has established protocols and trained personnel for rapid study set-up at facilities located in the U.S. and Europe.

We can either transfer your method to our labs or our team can work with you to adapt or develop a novel suitable method. In most cases, samples can be assayed on fresh or frozen samples and the results provided to you in a preferred format.

Contact one of our sites today to see how ABL can help you advance your product!

U.S. contact Europe contact